In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients

Transplantation

Volumn 67, Issue 2, 1999, Pages 253-258

  Vallhonrat, Heather ^a   Williams, Winfred W ^a   Cosimi, A Benedict ^a   Tolkoff Rubin, Nina ^a   Ginns, Leo C ^a   Wain, John C ^a   Preffer, Frederic ^b   Olszak, Iwona ^b   Wee, Siewlin ^a   Delmonico, Francis L ^a   Pascual, Manuel ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CD4 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYLPREDNISOLONE; OKT 3; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; FEMALE; FLOW CYTOMETRY; HEMODYNAMICS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; NEUTROPHIL; PRIORITY JOURNAL;

ADULT; AGED; BLOOD PRESSURE; COMPLEMENT ACTIVATION; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3B; COMPLEMENT C4; COMPLEMENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MODELS, CHEMICAL; MUROMONAB-CD3; PEPTIDE FRAGMENTS;

EID: 0033608102     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901270-00011     Document Type: Article

References (29)

1. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308.
2. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
3. Pascual M, Rubin RH, Cosimi AB. Minimizing the toxicity of antilymphocyte antibody therapy. Transplant Proc 1996; 28: 2113.
4. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
5. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Engl J Med 1989; 320: 1420.
6. Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome: dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
7. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.
8. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61: 224.
9. Wee S, Pascual M, Eason JD, et al. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation 1997; 63: 570.
10. Busing M, Mellert J, Greger B, Hopt UT. Acute pulmonary insufficiency due to OKT3 therapy. Transplant Proc 1990; 22: 1779.
11. Raasveld MHM, Bemelman FJ, Schellekens PThA, et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side-effects. Kidney Int 1993; 43: 1140.
12. Colvin RB, Preffer FI. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies. Clin Lab Med 1991; 11: 1.
13. Preffer FI. Diagnostic cytometry. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic immunopathology, 2nd ed. New York: Raven Press, 1993: 725.
14. Wissing KM, Morelon E, Legendre C, et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64: 999.
15. Thadhani R, Pascual M, Bonventre J. Acute renal failure. N Engl J Med 1996; 334: 1448.
16. Pascual M, Tolkoff-Rubin N, Schifferli JA. Is adsorption an important characteristic of dialysis membranes? Kidney Int 1996; 49: 309.
17. Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP. C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 1993; 43(suppl 41): S-221.
18. Bemelman FJ, Buysmann S, Yong SL, et al. Biphasic granulocytopenia after administration of the first dose of OKT3. J Lab Clin Med 1995; 126: 571.
19. Buysmann S, Bemelman J, Schellekens PTA, et al. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87: 404.
20. Pradier O, Surquin M, Stordeur P, et al. Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody. Blood 1996; 87: 3768.
21. Combe C, Pourtein M, de Precigout V, et al. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 1994; 24: 437.
22. Arnaout MA, Hakim RM, Todd RF, et al. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457.
23. Kaupke CJ, Zhang J, Cesario T, et al. Effect of hemodialysis on leukocyte adhesion receptor expression. Am J Kidney Dis 1996; 27: 244.
24. Chenoweth DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass. N Engl J Med 1981; 304: 497.
25. Pruitt SK, Bollinger RR, Collins BH, et al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63: 900.
26. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564.
27. Buysmann S, Hack CE, van Diepen FNJ, Surachno J, ten Berge IJM. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation 1997; 64: 1620.
28. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trials using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457.
29. Gazzano-Santoro H, Ralph P, Ryskamp TC, et al. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 1997; 202: 163.